

## Special Issue

# Systemic Therapies in Melanoma

### Message from the Guest Editors

In the last few years, the appraisal of the genetic background of melanoma has allowed us to identify key driver genes with oncogenic mutations and develop targeted therapies for advanced melanomas. The significant rate of response of the high mutation burden identified in skin melanomas to immunotherapy and combined therapy with checkpoint inhibitors has recently led to an impressive improvement in the 5-year overall survival in advanced skin melanoma patients. These changes, however, were not observed in metastatic uveal melanomas. This Special Issue aims to present articles assessing recent advances in systemic therapy for advanced skin and other melanomas.

---

### Guest Editors

Dr. Alexandre Moulin

Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland

Prof. Olivier Michielin

Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland

---

### Deadline for manuscript submissions

closed (28 February 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/45774](https://mdpi.com/si/45774)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)